Education
About Us
Working with TipRanks
Follow Us
Adocia SA (ADOCY)
OTHER OTC:ADOCY
ADOCY Stock Chart & Stats
$10.30
$0.00(0.00%)
At close: 4:00 PM EDT
$10.30
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.56 - $12.55
Previous CloseN/A
Volume30.00
Average Volume (3M)0.00
Market Cap
$189.77M
Enterprise Value$79.39M
Total Cash (Recent Filing)$7.53M
Total Debt (Recent Filing)$11.83M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Mar 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,298,424
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)-54.61
Price to Sales (P/S)18.10
P/FCF Ratio-10.65
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue6.88
Enterprise Value/Gross Profit67.82
Enterprise Value/Ebitda16.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ADOCY FAQ
What was Adocia SA’s price range in the past 12 months?
Adocia SA lowest stock price was $3.56 and its highest was $12.55 in the past 12 months.
What is Adocia SA’s market cap?
Adocia SA’s market cap is $189.77M.
When is Adocia SA’s upcoming earnings report date?
Adocia SA’s upcoming earnings report date is Mar 12, 2026 which is in 123 days.
How were Adocia SA’s earnings last quarter?
Currently, no data Available
Is Adocia SA overvalued?
According to Wall Street analysts Adocia SA’s price is currently Overvalued.
Does Adocia SA pay dividends?
Adocia SA does not currently pay dividends.
What is Adocia SA’s EPS estimate?
Adocia SA’s EPS estimate is -0.06.
How many shares outstanding does Adocia SA have?
Adocia SA has 18,298,424 shares outstanding.
What happened to Adocia SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adocia SA?
Currently, no hedge funds are holding shares in ADOCY
Company Description
Adocia SA
Adocia (ADOCY) is a biotechnology company specializing in the development of innovative therapeutic solutions for diabetes and other metabolic diseases. The company focuses on creating advanced formulations of insulin and other peptides that aim to improve treatment efficacy and patient compliance. Adocia's core products include its proprietary formulations of insulin, such as BioChaperone® technology, which enhances the pharmacokinetics of insulin treatments, as well as other peptide-based therapies designed for various metabolic disorders.
Technical Analysis
Achieve Life Sciences
―
Fate Therapeutics
―
Crescent Biopharma
―
C4 Therapeutics
―
Actuate Therapeutics, Inc.
―